Calculate total daily morphine milligram equivalents (MME) from multiple opioids with CDC risk thresholds, equianalgesic conversion, and naloxone guidance.
Morphine milligram equivalents (MME) provide a standardized way to compare doses across different opioid medications. The CDC 2022 Clinical Practice Guideline for Prescribing Opioids uses daily MME thresholds to guide risk assessment — recommending avoidance of increases to ≥ 50 MME/day without careful reassessment and special precautions at ≥ 90 MME/day. Higher daily MME is associated with progressively higher overdose risk: patients on ≥ 100 MME/day have nearly 9-fold increased overdose risk compared to patients on < 20 MME/day.
This calculator converts up to three concurrent opioids to total daily MME using established equianalgesic conversion factors from the CDC, CMS, and clinical pharmacology references. It provides CDC-aligned risk stratification, overdose risk estimates, naloxone co-prescribing recommendations, and benzodiazepine interaction warnings. The breakdown table shows each medication's contribution to total MME, helping identify opportunities for dose reduction or consolidation.
Equianalgesic conversions are approximations with significant inter-patient variability. Methadone conversions are particularly complex due to dose-dependent ratios, long and variable half-life, and QTc prolongation risk. When rotating opioids, standard practice is to reduce the calculated equianalgesic dose by 25-50% to account for incomplete cross-tolerance.
Accurate MME calculation is essential for safe opioid prescribing, regulatory compliance, and patient safety. This calculator simplifies multi-opioid conversions, provides CDC-aligned risk assessment, identifies naloxone co-prescribing needs, and flags dangerous benzodiazepine co-prescriptions. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation.
Total daily MME = Σ (daily dose × conversion factor) for each opioid. Conversion factors: morphine oral = 1.0, oxycodone = 1.5, hydromorphone oral = 4.0, fentanyl patch (mcg/hr) × 2.4, codeine = 0.15, tramadol = 0.1.
Result: 90 MME/day — Very high risk. Naloxone co-prescribing recommended.
Oxycodone 10 mg × 4 = 40 mg/day × 1.5 = 60 MME. Morphine 15 mg × 2 = 30 mg/day × 1.0 = 30 MME. Total = 90 MME/day, which places the patient at the very high risk threshold per CDC 2022 guidelines.
The 2022 CDC Clinical Practice Guideline replaced the controversial 2016 version, which was sometimes misapplied as inflexible dose limits leading to patient harm through forced tapers. The 2022 guideline emphasizes individualized assessment, shared decision-making, and avoidance of abrupt discontinuation. Key recommendations: use the lowest effective dose, avoid increasing to ≥ 50 MME/day without reassessment, consider offering naloxone at ≥ 50 MME/day, and use PDMP data to identify concurrent prescriptions. The guideline explicitly states that specific numeric thresholds should not be applied as rigid ceilings — clinical judgment remains paramount.
In 2022, over 80,000 Americans died from opioid-involved overdose deaths. While the current crisis is driven primarily by illicitly manufactured fentanyl, prescription opioid misuse remains a significant contributor, and most people with opioid use disorder initially encountered opioids through prescriptions. Accurate MME calculation, PDMP utilization, naloxone co-prescribing, and multimodal pain management are evidence-based strategies for reducing prescription opioid morbidity and mortality while maintaining access for patients who genuinely benefit from opioid therapy.
Opioid rotation (switching from one opioid to another) is a valuable strategy when a patient experiences inadequate pain relief despite dose increases, intolerable side effects, or pharmacokinetic issues. The key steps are: calculate the total daily MME of the current regimen, convert to the new opioid using equianalgesic ratios, reduce the calculated dose by 25-50%, and titrate based on response. The reduction accounts for incomplete cross-tolerance — the patient may be tolerant to the current opioid but not fully tolerant to the new one.
An MME is a conversion factor that expresses the dose of any opioid as the equivalent dose of oral morphine. For example, 10 mg of oral oxycodone has a conversion factor of 1.5, so it equals 15 MME. This standardization allows comparison of total opioid burden across different medications. The CDC uses MME thresholds to guide prescribing risk assessment.
Epidemiologic studies show that patients on ≥ 90 MME/day have approximately 9 times the overdose risk compared to patients on < 20 MME/day. The CDC 2022 guideline recommends that clinicians should carefully reassess evidence of individual benefits and risks when considering increasing dosage to ≥ 50 MME/day, and should avoid increasing dosage to ≥ 90 MME/day or carefully justify the decision. However, this is not intended as a rigid dose ceiling — some patients with cancer pain or severe chronic pain may appropriately need higher doses.
Methadone has unique pharmacology: incomplete cross-tolerance with other mu-opioid agonists, NMDA receptor antagonism, dose-dependent conversion ratios (the ratio increases dramatically at higher doses), extremely long and variable half-life (8-59 hours), and risk of QTc prolongation and torsades de pointes. A patient on morphine 60 mg/day converts to methadone at a 4:1 ratio, but a patient on morphine 300 mg/day converts at 12:1. Methadone rotations should only be performed by experienced clinicians with careful monitoring.
CDC 2022 recommends co-prescribing naloxone for patients on ≥ 50 MME/day, concurrent benzodiazepines, history of overdose or substance use disorder, or other factors that increase overdose risk (sleep apnea, renal impairment, older age). Intranasal naloxone (Narcan 4 mg) should be prescribed with education for the patient and household members on overdose recognition and naloxone administration.
No. Equianalgesic ratios are based on single-dose studies in opioid-naïve populations and have significant inter-patient variability (2-5 fold). Factors affecting individual response include genetics (CYP2D6 polymorphisms affect codeine and tramadol metabolism), organ function (renal impairment accumulates active metabolites of morphine and hydromorphone), age, concurrent medications, and tolerance level. Always reduce the calculated dose by 25-50% when rotating to a new opioid.
The CDC 2022 Clinical Practice Guideline is intended for outpatient clinicians prescribing opioids for chronic pain in adults, excluding pain management related to sickle cell disease, cancer-related pain treatment, palliative care, and end-of-life care. Patients with cancer pain or those receiving palliative/hospice care may appropriately need higher opioid doses without the same threshold-based restrictions.